Abstract
Background: The addition of two years of abemaciclib treatment to standard adjuvant endocrine therapy in all patients with high risk ER+, HER2- early-breast cancer (EBC) has been approved by the European Medicines Agency (EMA). Implementation of this treatment in this setting creates additional burden on patients and will increase health care costs. Pre-selection of high-risk patients using detection of minimal residual disease (MRD) by determination of circulating tumor DNA (ctDNA) in plasma during follow-up is highly promising and could select the patients who will benefit from abemaciclib treatment.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
